Course
Essentials of Drug Discovery and Development
BIOL-40379
Learn the Drug Discovery and Development Process
This course is designed to provide students with an overview of the process of drug discovery and development through online lectures and discussions. Students will gain an understanding of the key stages involved in bringing a new drug to market, from initial target identification through clinical trials, regulatory approval, and commercialization.This course will benefit both students without prior knowledge of pharmaceutical discovery and development, as well as working professionals aiming to further their understanding of their vocation.Topics
- History and Overview of Drug Discovery & Development and the Biopharmaceutical Industry
- Drug Targets
- Assays for Drug Discovery
- Drug Modalities
- Biology and Pharmacology in Drug Discovery
- Preclinical Development and Safety
- Clinical Trials and Development
- Intellectual Property
- Regulatory Affairs, Commerical Launch, and Marketing
Learning Objectives
- Understand the modern drug discovery and development process
- Understand how drug targets are chosen and evaluated
- Become familiar with the four major drug modalities: small molecules, biologics, nucleic acids, and cell therapies
- Understand the clinical trials process and how it is conducted
Prerequisites
Format
Course Information
Online
3.00 units
$845.00
Course sessions
Closed
Closed
Chris Larson, PhD, has more than 25 years of drug discovery and development experience in public and private biotech and global pharmaceutical companies. He is currently President of Research and Development for Levator Therapeutics.
Dr. Larson was a member of the research teams for three marketed drugs and has led or co-led discovery research programs resulting in 10 IND filings and clinical development.
He previously served as US head and associate global head of Takeda Pharmaceuticals’ Cardiovascular and Metabolic Diseases Drug Discovery Unit, where he pioneered an open innovation academic collaboration program. He co-founded Vasa Therapeutics and SNO bio, and helped launch and grow Karus Therapeutics. He serves on several scientific advisory boards.
He is an instructor in the Sanford Burnham Prebys (SBP) Medical Discovery Institute’s Graduate School of Biomedical Sciences after serving as SBP’s vice president of drug discovery as well as principal investigator of his NIH-funded research laboratory. He also served as co-principal investigator for SBP’s core grant as part of the Chemical Biology Consortium, National Cancer Institute Experimental Therapeutics program.
Dr. Larson has authored or co-authored more than 30 peer-reviewed scientific publications, reviews, and book chapters.
As a reviewer, he participated for several years on the National Institutes of Health: Bioengineering Sciences and Technologies Study Section, the Grant Review Panel for the Obesity Society, and the Early Career Research Grants Review Committee for the Obesity Society.
He is a past review editor for the journal Pharmacology of Anti-Cancer Drugs, and has been an ad hoc reviewer for Bioorganic & Medicinal Chemistry Letters, The International Journal of Biochemistry & Cell Biology, Journal of Pharmacology and Experimental Therapeutics, and Arthritis & Rheumatism.
Dr. Larson earned his B.A. and Ph.D. in chemistry from Carleton College and Harvard University, respectively, and did postdoctoral research at the Salk Institute in cancer biology.
Full Bio
Section ID:
183775
Class type:
Online Asynchronous.
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
No textbook required.
Policies:
- No refunds after: 10/14/2024
Schedule:
No information available at this time.
Instructor: Christopher Larson
Christopher Larson
Dr. Larson was a member of the research teams for three marketed drugs and has led or co-led discovery research programs resulting in 10 IND filings and clinical development.
He previously served as US head and associate global head of Takeda Pharmaceuticals’ Cardiovascular and Metabolic Diseases Drug Discovery Unit, where he pioneered an open innovation academic collaboration program. He co-founded Vasa Therapeutics and SNO bio, and helped launch and grow Karus Therapeutics. He serves on several scientific advisory boards.
He is an instructor in the Sanford Burnham Prebys (SBP) Medical Discovery Institute’s Graduate School of Biomedical Sciences after serving as SBP’s vice president of drug discovery as well as principal investigator of his NIH-funded research laboratory. He also served as co-principal investigator for SBP’s core grant as part of the Chemical Biology Consortium, National Cancer Institute Experimental Therapeutics program.
Dr. Larson has authored or co-authored more than 30 peer-reviewed scientific publications, reviews, and book chapters.
As a reviewer, he participated for several years on the National Institutes of Health: Bioengineering Sciences and Technologies Study Section, the Grant Review Panel for the Obesity Society, and the Early Career Research Grants Review Committee for the Obesity Society.
He is a past review editor for the journal Pharmacology of Anti-Cancer Drugs, and has been an ad hoc reviewer for Bioorganic & Medicinal Chemistry Letters, The International Journal of Biochemistry & Cell Biology, Journal of Pharmacology and Experimental Therapeutics, and Arthritis & Rheumatism.
Dr. Larson earned his B.A. and Ph.D. in chemistry from Carleton College and Harvard University, respectively, and did postdoctoral research at the Salk Institute in cancer biology.
Add To Cart
Add To Cart
Chris Larson, PhD, has more than 25 years of drug discovery and development experience in public and private biotech and global pharmaceutical companies. He is currently President of Research and Development for Levator Therapeutics.
Dr. Larson was a member of the research teams for three marketed drugs and has led or co-led discovery research programs resulting in 10 IND filings and clinical development.
He previously served as US head and associate global head of Takeda Pharmaceuticals’ Cardiovascular and Metabolic Diseases Drug Discovery Unit, where he pioneered an open innovation academic collaboration program. He co-founded Vasa Therapeutics and SNO bio, and helped launch and grow Karus Therapeutics. He serves on several scientific advisory boards.
He is an instructor in the Sanford Burnham Prebys (SBP) Medical Discovery Institute’s Graduate School of Biomedical Sciences after serving as SBP’s vice president of drug discovery as well as principal investigator of his NIH-funded research laboratory. He also served as co-principal investigator for SBP’s core grant as part of the Chemical Biology Consortium, National Cancer Institute Experimental Therapeutics program.
Dr. Larson has authored or co-authored more than 30 peer-reviewed scientific publications, reviews, and book chapters.
As a reviewer, he participated for several years on the National Institutes of Health: Bioengineering Sciences and Technologies Study Section, the Grant Review Panel for the Obesity Society, and the Early Career Research Grants Review Committee for the Obesity Society.
He is a past review editor for the journal Pharmacology of Anti-Cancer Drugs, and has been an ad hoc reviewer for Bioorganic & Medicinal Chemistry Letters, The International Journal of Biochemistry & Cell Biology, Journal of Pharmacology and Experimental Therapeutics, and Arthritis & Rheumatism.
Dr. Larson earned his B.A. and Ph.D. in chemistry from Carleton College and Harvard University, respectively, and did postdoctoral research at the Salk Institute in cancer biology.
Full Bio
Section ID:
187226
Class type:
Online Asynchronous.
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
All course materials are included unless otherwise stated.
Policies:
- No refunds after: 4/7/2025
Schedule:
No information available at this time.
Instructor: Christopher Larson
Christopher Larson
Dr. Larson was a member of the research teams for three marketed drugs and has led or co-led discovery research programs resulting in 10 IND filings and clinical development.
He previously served as US head and associate global head of Takeda Pharmaceuticals’ Cardiovascular and Metabolic Diseases Drug Discovery Unit, where he pioneered an open innovation academic collaboration program. He co-founded Vasa Therapeutics and SNO bio, and helped launch and grow Karus Therapeutics. He serves on several scientific advisory boards.
He is an instructor in the Sanford Burnham Prebys (SBP) Medical Discovery Institute’s Graduate School of Biomedical Sciences after serving as SBP’s vice president of drug discovery as well as principal investigator of his NIH-funded research laboratory. He also served as co-principal investigator for SBP’s core grant as part of the Chemical Biology Consortium, National Cancer Institute Experimental Therapeutics program.
Dr. Larson has authored or co-authored more than 30 peer-reviewed scientific publications, reviews, and book chapters.
As a reviewer, he participated for several years on the National Institutes of Health: Bioengineering Sciences and Technologies Study Section, the Grant Review Panel for the Obesity Society, and the Early Career Research Grants Review Committee for the Obesity Society.
He is a past review editor for the journal Pharmacology of Anti-Cancer Drugs, and has been an ad hoc reviewer for Bioorganic & Medicinal Chemistry Letters, The International Journal of Biochemistry & Cell Biology, Journal of Pharmacology and Experimental Therapeutics, and Arthritis & Rheumatism.
Dr. Larson earned his B.A. and Ph.D. in chemistry from Carleton College and Harvard University, respectively, and did postdoctoral research at the Salk Institute in cancer biology.